Antipsychotic-like effect of minocycline in a rat model

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 10, 2014, Pages 3354-3361

  Dokuyucu, Recep ^a   Kokacya, Hanifi ^a   Inanir, Sema ^b   Copoglu, Umit Sertan ^a   Erbas, Oytun ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b Department of Psychiatry Governor Recep Yazicioglu Mental Health and Disease Hospital   (Turkey)

^c GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Minocycline; Novelty induced rearing; Psychosis; Schizophrenia; Stereotypic behavior

Indexed keywords

APOMORPHINE; CHLORPROMAZINE; MALONALDEHYDE; MINOCYCLINE;

ADULT; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIPSYCHOTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; GNAWING; KRUSKAL WALLIS TEST; LIPID PEROXIDATION; LOCOMOTION; MALE; NEUROPROTECTION; NONHUMAN; POST HOC ANALYSIS; PSYCHOSIS; RANK SUM TEST; RAT; REARING; SNIFFING; STEREOTYPY;

EID: 84910026155     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. van Os J and Kapur S. Schizophrenia. Lancet 2009; 374: 635-645.
2. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 20-34.
3. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-152.
4. Abi-Dargham A and Moore H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 2003; 9: 404-416.
5. Kuepper R, Skinbjerg M and Abi-Dargham A. The dopamine dysfunction in schizophrenia revisited: new insights into topography and course. Handb Exp Pharmacol 2012; 1-26.
6. Kapur S and Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics: A new hypothesis. Am J Psychiatry 2001; 158: 360-369.
7. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38.
8. Pazvantoglu O, Selek S, Okay IT, Sengul C, Karabekiroglu K, Dilbaz N and Erel O. Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile. Psychiatry Clin Neurosci 2009; 63: 693-700.
9. Padurariu M, Ciobica A, Dobrin I and Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett 2010; 479: 317-320.
10. Kunz M, Gama CS, Andreazza AC, Salvador M, Cereser KM, Gomes FA, Belmonte-de-Abreu PS, Berk M and Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1677-1681.
11. Wang JF, Shao L, Sun X and Young LT. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 2009; 11: 523-529.
12. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009; 22: 75-83.
13. Ponzoni S. Macrophages-mediated neurotoxic effects of intra-nigral manganese administration are attenuated by minocycline. Neurosci Lett 2012; 506: 136-140.
14. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. J Am Vet Med Assoc 1980; 176: 1061-1068.
15. Barza M, Brown RB, Shanks C, Gamble C and Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975; 8: 713-720.
16. Hashimoto K and Ishima T. A novel target of action of minocycline in NGF-induced neurite outgrowth in PC12 cells: translation initiation [corrected] factor eIF4AI. PLoS One 2010; 5: e15430.
17. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I and Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149.
18. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T and Horiguchi J. Possible antipsychotic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 304-307.
19. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M and Hashimoto K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 336-339.
20. Zhang L, Shirayama Y, Shimizu E, Iyo M and Hashimoto K. Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. Eur J Pharmacol 2006; 544: 1-9.
21. Hashimoto K, Sawa A and Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007; 62: 1310-1316.
22. Mizoguchi H, Takuma K, Fukakusa A, Ito Y, Nakatani A, Ibi D, Kim HC and Yamada K. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 2008; 196: 233-241.
23. Zhang L, Kitaichi K, Fujimoto Y, Nakayama H, Shimizu E, Iyo M and Hashimoto K. Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1381-1393.
24. Levkovitz Y, Levi U, Braw Y and Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007; 1154: 154-162.
25. Juckel G, Manitz MP, Brune M, Friebe A, Heneka MT and Wolf RJ. Microglial activation in a neuroinflammational animal model of schizophrenia--a pilot study. Schizophr Res 2011; 131: 96-100.
26. Dean OM, Data-Franco J, Giorlando F and Berk M. Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012; 26: 391-401.
27. Chaudhry IB, Hallak J, Husain N, Minhas F, Stirling J, Richardson P, Dursun S, Dunn G and Deakin B. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-1193.
28. Zhang L, Shirayama Y, Iyo M and Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007; 32: 2004-2010.
29. Ajayi AA and Ukponmwan OE. Possible evidence of angiotensin II and endogenous opioid modulation of novelty-induced rearing in the rat. Afr J Med Med Sci 1994; 23: 287-290.
30. Amos S, Abbah J, Chindo B, Edmond I, Binda L, Adzu B, Buhari S, Odutola AA, Wambebe C and Gamaniel K. Neuropharmacological effects of the aqueous extract of Nauclea latifolia root bark in rats and mice. J Ethnopharmacol 2005; 97: 53-57.
31. Dong SM, Kim YG, Heo J, Ji MK, Cho JW and Kwak BS. YKP1447, A Novel Potential Atypical Antipsychotic Agent. Korean J Physiol Pharmacol 2009; 13: 71-78.
32. Reavill C, Kettle A, Holland V, Riley G and Blackburn TP. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol 1999; 126: 572-574.
33. Ohkawa H, Ohishi N and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
34. Chaves C, de Marque CR, Wichert-Ana L, Maia-de-Oliveira JP, Itikawa EN, Crippa JA, Zuardi AW, Todd KG, Baker GB, Dursun SM and Hallak JE. Functional neuroimaging of minocycline's effect in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 550-552.
35. Miyaoka T, Wake R, Furuya M, Liaury K, Ieda M, Kawakami K, Tsuchie K, Taki M, Ishihara K, Araki T and Horiguchi J. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2012; 37: 222-226.
36. Miyaoka T. Clinical potential of minocycline for schizophrenia. CNS Neurol Disord Drug Targets 2008; 7: 376-381.
37. Liaury K, Miyaoka T, Tsumori T, Furuya M, Hashioka S, Wake R, Tsuchie K, Fukushima M, Limoa E, Tanra AJ and Horiguchi J. Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 50: 184-190.
38. Sotoing Taiwe G, Ngo Bum E, Talla E, Dawe A, Okomolo Moto FC, Temkou Ngoupaye G, Sidiki N, Dabole B, Djomeni Dzeufiet PD, Dimo T and De Waard M. Antipsychotic and sedative effects of the leaf extract of Crassocephalum bauchiense (Hutch.) Milne-Redh (Asteraceae) in rodents. J Ethnopharmacol 2012; 143: 213-220.
39. Dixit TS, Sharma AN, Lucot JB and Elased KM. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav 2013; 114-115: 38-41.
40. Stahl SM. Neuroscientific Basis and Practical Applications Cambridge University Press; 2000.
41. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002-1012.
42. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F and Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett 2004; 372: 157-160.
43. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, Ruther E, Emrich HM, Schneider U and Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005; 17: 227-231.
44. Gama CS, Salvador M, Andreazza AC, Kapczinski F and Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizo-phrenia: a study of patients treated with haloperidol or clozapine. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 512-515.
45. Dakhale GN, Khanzode SD, Khanzode SS and Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005; 182: 494-498.